In 2026, the global biopharmaceutical industry continues to expand. The development of emerging fields such as cell and gene therapy, and monoclonal antibodies has driven the upgrading of pharmaceutical water standards, leading to a surge in demand for core equipment like multi-effect water distillers. Data shows that the biopharmaceutical sector accounts for over 35% of the global market for purified water treatment equipment, with intelligence, energy saving and compliance of Water for Injection (WFI) preparation equipment becoming the focus of competition.
With the tightening of the 2026 new pharmacopoeia and international standards such as FDA and EMA, pharmaceutical enterprises have higher requirements for pyrogen-free and high-purity injection water. The dual-carbon goal also promotes energy-saving upgrades of equipment. Traditional water distillers are gradually replaced by high-efficiency models, and multi-effect water distillers with eight or more effects have become mainstream, with thermal efficiency exceeding 82% and unit water production energy consumption dropping nearly 50% compared with ten years ago, greatly reducing operating costs.
Intelligence is another major trend. The new generation of multi-effect water distillers integrates PLC control, 485 remote communication and other functions, realizing real-time water quality monitoring and data traceability to meet cGMP and FDA requirements; the modular design shortens the installation cycle to less than 15 days, adapting to pharmaceutical enterprises’ expansion needs.
At present, pharmaceutical enterprises’ demand has shifted to full-life-cycle water treatment solutions, and equipment balancing compliance, energy saving and intelligence is more favored. Hebei Guanyu Environmental Protection’s high-efficiency and energy-saving multi-effect water distillers comply with USP, EP and Chinese Pharmacopoeia standards, providing IQ/OQ/PQ verification documents to help global pharmaceutical enterprises achieve safe and low-carbon WFI preparation.
